🇺🇸 FDA
Pipeline program

Ivonescimab Injection

SMT112-3003

Phase 3 mab active

Quick answer

Ivonescimab Injection for Non-Small Cell Lung Cancer is a Phase 3 program (mab) at Summit Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Non-Small Cell Lung Cancer
Phase
Phase 3
Modality
mab
Status
active

Clinical trials